XML 85 R36.htm IDEA: XBRL DOCUMENT
v3.22.4

Development and Other Agreements - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2018 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | [1],[2] | Dec. 31, 2019 | Dec. 28, 2018
Development Agreements [Line Items] |  |  |  |  |  |  |  |  |
Collaborative research and development fee |  |  |  | $ 0.0 | $ 87.1 | [1],[2] | $ 0.0 |  |
Shares Issued In Connection With The Restated Collaboration Agreement |  |  |  | 2,945,508 |  |  |  |  |
Gross Carrying Amount | $ 195.5 | $ 42.8 |  | $ 195.5 | $ 42.8 |  |  |  |
Verily Life Sciences | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |  |  |
Amortization period | 64 months |  |  |  |  |  |  |  |
Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |  |  |
Closing stock price (usd per share) |  |  |  |  |  |  |  |  | $ 29.57
Initial payment on collaborative agreement |  |  | $ 250.0 |  |  |  |  |  |
Issuance of common stock in connection with acquisition, shares (in shares) |  |  | 7,363,772 |  |  |  |  |  |
Collaborative research and development fee |  | $ 87.1 | $ 217.7 |  |  |  |  |  |
Collaborative Arrangement, Milestone Payments | Verily Life Sciences | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |  |  |
Collaborative research and development fee |  |  |  |  |  |  |  | $ 3.2 |
Gross Carrying Amount | $ 152.4 |  |  | $ 152.4 |  |  |  |  |
Potential future common stock issuable (in shares) |  |  |  |  |  |  |  |  | 5,154,640
[1] | * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[2] | * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.

X
- Definition Collaborative Arrangement, Upfront Fee + References No definition available. + Details
Name: | dxcm_CollaborativeArrangementUpfrontFee
Namespace Prefix: | dxcm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Research and Development Fee + References No definition available. + Details
Name: | dxcm_CollaborativeResearchAndDevelopmentFee
Namespace Prefix: | dxcm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development Agreements [Line Items] + References No definition available. + Details
Name: | dxcm_DevelopmentAgreementsLineItems
Namespace Prefix: | dxcm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Future Common Stock Issuable, Shares, New Issues + References No definition available. + Details
Name: | dxcm_PotentialFutureCommonStockIssuableSharesNewIssues
Namespace Prefix: | dxcm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Shares Issued In Connection With The Restated Collaboration Agreement + References No definition available. + Details
Name: | dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement
Namespace Prefix: | dxcm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 340 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=dxcm_VerilyLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementInitialPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |